4.6 Article

Systemic and Ocular Determinants of Peripapillary Retinal Nerve Fiber Layer Thickness Measurements in the European Eye Epidemiology (E3) Population

期刊

OPHTHALMOLOGY
卷 125, 期 10, 页码 1526-1536

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ophtha.2018.03.026

关键词

-

资金

  1. BrightFocus Foundation
  2. Lions Foundation
  3. Grimshaw-Gudewicz Foundation
  4. Research to Prevent Blindness
  5. National Eye Institute Core Grant [P30EYE003790]
  6. Thea Pharma
  7. Bayer
  8. Novartis
  9. Laboratoires Thea (Clermont-Ferrand, France)
  10. University of Bordeaux (Bordeaux, France)
  11. Fondation Voir et Entendre (Paris, France)
  12. Caisse Nationale de Solidarite pour l'Autonomie CNSA (CNSA)
  13. Novartis Pharma AG
  14. Leipzig Research Centre for Civilization Diseases (LIFE)
  15. European Union
  16. European Regional Development Fund
  17. Free State of Saxony [713-241202, 14505/2470, 14575/2470]
  18. Inter-regional grant (PHRC)
  19. Regional Council of Burgundy
  20. INRA
  21. CNRS
  22. Universite de Bourgogne
  23. Regional Council of Burgundy France (PART Agrale 1)
  24. FEDER (European Funding for Regional Economic Development)
  25. French Government [ANR-11-LABX-0021-01-LipSTIC Labex]
  26. Erasmus MC and Erasmus University, Rotterdam, Netherlands
  27. Organization for the Health Research and Development (ZonMw)
  28. Research Institute for Diseases in the Elderly (RIDE)
  29. Ministry of Education, Culture and Science
  30. Ministry for Health, Welfare and Sports
  31. European Commission (DG XII)
  32. Municipality of Rotterdam
  33. European Union's Horizon 2020 research and innovation program [668648]
  34. NWO Graduate Programme 2010 BOO [022.002.023]
  35. National Institute of Health (Bethesda, MD) [R01 EY019112, R01 EY018853]
  36. Veterans Administration Grant [I01 CX000119]
  37. Arnold and Mabel Beckman Initiative for Macular Research
  38. International Glaucoma Association (2013 research award)
  39. Wellcome Trust
  40. National Institute for Health Research-Bio-Resource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust
  41. King's College London
  42. Else Kroner-Fresenius-Stiftung [GSO/EKFS 16]
  43. Jackstadt Stiftung
  44. MRC [MR/K023721/1] Funding Source: UKRI
  45. NATIONAL EYE INSTITUTE [R01EY018853] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Purpose: To investigate systemic and ocular determinants of peripapillary retinal nerve fiber layer thickness (pRNFLT) in the European population. Design: Cross-sectional meta-analysis. Participants: A total of 16 084 European adults from 8 cohort studies (mean age range, 56.9 +/- 12.3-82.1 +/- 4.2 years) of the European Eye Epidemiology (E3) consortium. Methods: We examined associations with pRNFLT measured by spectral-domain OCT in each study using multivariable linear regression and pooled results using random effects meta-analysis. Main Outcome Measures: Determinants of pRNFLT. Results: Mean pRNFLT ranged from 86.8 +/- 21.4 mu m in the Rotterdam Study I to 104.7 +/- 12.5 mu m in the Rotterdam Study III. We found the following factors to be associated with reduced pRNFLT: Older age (beta = -0.38 mu m/year; 95% confidence interval [CI], -0.57 to -0.18), higher intraocular pressure (10P) (beta = -0.36 mu m/mmHg; 95% CI, -0.56 to -0.15), visual impairment (beta = -5.50 mu m; 95% CI, -9.37 to -1.64), and history of systemic hypertension (beta = -0.54 mu m; 95% CI, -1.01 to -0.07) and stroke (beta = -1.94 mu m; 95% CI, -3.17 to -0.72). A suggestive, albeit nonsignificant, association was observed for dementia (beta = -3.11 mu m; 95% CI, -6.22 to 0.01). Higher pRNFLT was associated with more hyperopic spherical equivalent (beta = 1.39 mu m/diopter; 95% CI, 1.19-1.59) and smoking (beta = 1.53 mu m; 95% CI, 1.00-2.06 for current smokers compared with never-smokers). Conclusions: In addition to previously described determinants such as age and refraction, we found that systemic vascular and neurovascular diseases were associated with reduced pRNFLT. These may be of clinical relevance, especially in glaucoma monitoring of patients with newly occurring vascular comorbidities. (C) 2018 by the American Academy of Ophthalmology

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据